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Summary.-A study instigated by the British Breast Group and involving 3 centres
(Edinburgh, Glasgow and Liverpool) was carried out to compare 3 methods for the
estimation of urinary hydroxyproline. No significant difference between the first and
the second 24 h urine collection was found for each measure of urinary hydroxy-
proline, within laboratories and within patient groups. Reliable hydroxyproline
studies can, therefore, be performed on one 24 h urine collection.
The Grant and Ellis/Goldberg methods gave comparable results and the excretion
of hydroxyproline in the urine measured by either of these 2 methods could be used
to distinguish cases of breast cancer with osseous involvement (as demonstrated by
X-rays) from those without. The Hypronosticon Kit method was found to be unreliable
as it had 29.4% false negatives in breast-cancer patients with X-ray demonstrable
metastases.
The incidence of elevated urinary hydroxyproline excretion in breast-cancer
patients with negative X-rays was 11/14 (25%), 5/34 (15%) and 8/43 (19%) for the
Ellis/Goldberg, Hypronosticon and Grant methods respectively. No conclusion can
be drawn regarding the outcome of this group of patients because of the short period
of follow-up.
A NUMBER of clinical reports published
in recent years (Guzzo et al., 1969;
Cuschieri and Felgate, 1972; Cuschieri,
1973; Roberts et al., 1975; Powles et al.,
1975) have indicated the usefulness of
urinary hydroxyproline, particularly in
relation to the excretion of creatinine in
the detection of spread of breast cancer to
bone, and in monitoring the effects of
treatment for advanced disseminated
disease. In practice, there are certain
factors which militate against the more
widespread use of this test in the manage-
ment ofbreast cancer. The most important
of these relates to the measurement of
urinary hydroxyproline (OHP) for which
several procedures are available. Most of
the methods involve hydrolysis with acid
at l20°C (pressure cooker) although a
recent kit method (Hypronosticon test)
uses amberlite-resin-catalysed hydrolysis.
It is evident, therefore, that standardiz-
ation ofthemethodofestimationofurinary
OHP is necessary before any large scale
multicentre studies are instituted.
The aims ofthe study were as follows:
(1) To compare methods of urinary hy-
droxyproline estimation.
(2) To determine the most economic,
practicable and reproducible method.
PATIENTS AND METHODS
Criteria for admission.-Patients included
in the study had to have histologically proven
breast cancer. They were not to be on hor-
monal therapy or chemotherapy at the time
of testing. For the purpose of the study all
patients had to be admitted to hospital, and
entry into the study was restricted to patients
in the pre-operative period or more than 15
days after surgery.URINARY HYDROXYPROLINE IN BREAST CANCER
Two main groups of breast-cancer patients
were studied:
(i) X-ray+: 21 patients with X-ray-
demonstrable metastases. The age
range was 39-75 years (x = 58-1).
(ii) X-ray-: 44 patients aged 28-74 years
(i = 55-5). These patients had normal
skeletal X-ray surveys.
Controls.-A control population of 29
normal healthy female volunteers aged 20-68
years (x = 36.6) was also studied.
Urine collection.-Two 24h urine specimens
were collected on Days 3 and 4 whilst the
TABLE I.-Instructions toPatients on 4-day
Gelatin-free Diet
It is important that you do not eat or drink any-
thing included in the list offoods to be avoided; you
may eat as much as you like of the foods allowed.
Foods allowedfreely:
1. Eggs and fresh fish (not frozen or trinned).
2. Cheese (not processed), milk, butter, cream
(fresh).
3. Honey, sugar, tea, coffee, fruit juices, fruit
squashes, yoghurt.
4. Bread, plain cake, plain biscuits.
5. Cereals, porridge, rice, pasta.
6. All vegetagles, all fresh fruit.
7. Fats, oils, salt, pepper, vinegar, spices and herbs.
8. Boiled sweets, beer and wine.
Foods to be avoided:
1. Any form of meat-fresh, tinned, pies etc.
2. Any form of poultry.
3. Any form of fish except fresh fish.
4. Any meat or fish paste, meat or yeast extracts,
e.g. Bovril.
5. Processed cheese.
6. All soups, jellies, bottled sauces.
7. All cake except plain cake, icecream, jelly, instant
desserts, pie fillings, trifle, cream-filled biscuits.
8. All jams and marmalade.
9. All sweets and chocolates except boiled sweets.
Check the label on all bought foods and drinks for
gelatin, meat and fish.
patients and controls were on a 4-day gelatin-
free diet. The urine was collected in bottles
containing 8-0 g boric acid as a preservative.
Details of the diet are shown in Table I. A
50 ml sample from each 24h collection was
sent from each centre to the other 2 labora-
tories participating in the study.
Clinical data.-Height (bare feet) weight
(nude) and volume of each 24h urine collec-
tion were used to express the data relating to
the excretion of urinary hydroxyproline. A
complete list of all medications was obtained
for each patient.
Methods of estimation.-The urinary
hydroxyproline was estimated inLiverpool by
the modified Grant's semi-automated tech-
nique (Grant, 1964) in Edinburgh by the
Ellis and Goldberg method (1970) and in
Glasgow by the Organon (Hypronosticon) Kit
method. The preliminary hydrolysis of the
sample was by pressure cooker at 15 lb for
2 h. The urinary creatinine was measured by
the Technicon Auto-Analyser method com-
mon to all 3 centres.
Analysis of data.-The results were sub-
jected to computer analysis by the Statistics
Section of the Mersey Regional Health
Authority, and an allowance made for missing
data (specimens lost in transit) in all the
analyses.
RESULTS
Urinary hydroxyproline
(1) Controls.-These are shown in Table
II. Within each centre, no significant
difference was observed between the
results of the first and second 24h
urine collections. Comparison between
centres showed no significant difference
between the Grant and the Ellis/Goldberg
method but both gave significantly higher
TABLE II.-Controls Hydroxyproline Excretion
Method
(i) 1st 24h Collection
Ellis/Goldberg
Hfypronosticon
Grant
(ii) 2nd 24h Collection
Ellis/Goldberg
Hypronosticon
Grant
,umol/24 h/m2
xE s.e. n
90-4 6-0
50-8 5-5
94-7 7-4
29
21
28
91-4 8-3 19
65-1 6-7 16
92-6 10-3 17
,tmol/l urine
x s.e. n
117-94 11-78 29
75 - 46 11-86 21
123-30 13-58 28
121-43 11-86 19
84-50 10-61 16
112-60 9-72 17
Hydroxyproline/Creatinine
x 100
x s.e. n
1-700 0-118 29
1-192 0-152 21
1 -630 0-107 28
1 -639 0-106 19
1 -293 0- 177 16
1-641 0-155 17
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FIG.-Frequency distributions of urinary
hydroxyproline (OHP) in ,mol/24 h control
urine samples.
values than the Hypronosticon method
(P < 0.01). The frequency distribution of
the control values for urinary OHP
expressed in pmol/24 h obtained by the 3
methodsofestimationusedinthisstudyare
shown in the Fig.
(2) Breast cancer.-As there was no
significant difference between the first and
second 24h collections within each group,
all further comparisons used first readings
only.
X-ray+.-The raw data are shown in
Table III. A very close agreement was
obtained between the results obtained by
the Grant and the Ellis/Goldberg methods,
although the latter gave significantly
higher values (P < 0'02) for hydroxy-
proline/creatinine index during the first
24 h, but not during the second.
The results obtained by the Hypro-
nosticon method were significantly lower
thanthoseobtainedbythe other 2 methods
(P < 0 05, and <0.01). Of 17 patients
with radiologically demonstrable deposits,
5 had normal values for urinary OHP
when thiswas measured by the Hypronos-
ticon test, as opposed to 1/20 and 1/21
for the Ellis/Goldberg and Grant meth-
ods respectively.
X-ray-.-The raw data are shown in
Table IV. Fourteen patients had elevated
OHPby one or more methods. Again, there
was reasonable correlation only between
the results obtained by the Grant and
Ellis/Goldberg methods. For the X-ray-
group as a whole, the Ellis/Goldberg
resultswere significantly higherthaneither
the Grant or Hypronosticon data (P <
0*01).
Urinary creatinine
No significant differences were observed
between the laboratories for the urinary
creatinine values in both the control and
patient groups.
TABLE III.-Breast Cancer, X-ray+ Hydroxyproline Excretion
Method
(i) 18t 2 4h Collection
Ellis/Goldborg
Hypronosticon
Grant
(ii) 2nd 24h Collection
Ellis/Goldberg
Hypronosticon
Grant
,tmol/24 h/m2
x s.e. n
259-0 26-3 21
133 -7 19 -3 17
206 - 1 18-9 21
259*3 49-7 11
139 -1 33 -5 8
247-9 32-0 14
Hydroxyproline/Creatinine
,umol/l urine x 100
A n , s n
x s.e. n x s.e. n
387-4 59 3 21
196- 1 44-5 17
325- 1 51-0 21
302-8 68-5 11
153-6 50 5 8
314- 6 70 - 1 14
6 - 998 0 - 831 21
3 -953 0-491 17
5-583 0-624 21
6 - 887 1 -275 11
3-926 0-921 8
7 - 143 1 -958 14
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TABLE JV.-Breast Cancer-X-ray- Hydroxyproline Excretion
Hydroxyproline/Crea,tinine
,umol/24 h/M2 ,umol/l urine x 100
Method x s.e. n x s.e. n x s.e. n
(i) 1st 24h Collection
Ellis/Goldberg 103 - 8 6 - 6 44 118-8 7 - 8 44 2-512 0 - 169 38
Hypronosticon 61-3 6 - 2 34 71-2 6 - 9 34 1-658 0 - 179 33
Grant 80 6 5-1 43 91-4 5-8 43 1-658 0 - 179 43
(ii) 2nd 24h Collection
Ellis/Goldberg 105-0 8 2 27 116-1 9 -4 27 2 -520 0 - 173 27
Hypronosticon 78-1 8 - 2 19 82 - 9 8 - 3 19 1 - 966 0-215 19
Grant 85-8 9-8 20 94 2 11-5 20 1-926 0-124 20
DISCUSSION
This study has shown that the distribu-
tion of OHP in a healthy female popula-
tion is skewed. A good correlation was
found between the data (especially after
standardization) obtained by the Grant
and the Ellis/Goldberg methods. The
Hypronosticon results were more variable,
and tended to discriminate least between
the various groups. This method is based
on resin-catalysed hydrolysis. However,
the activity of the resin is dependent on
the cation concentration in the urine,
which is not a constant factor and may
account for the variability of the results
obtained by this method. Recovery rates
with the Hypronosticon Kit method using
prolylhydroxy-proline as an internal
standard were found to vary from 30 to
82%.
No significant difference was observed
for each measure of OHP, within labora-
tories and within patient groups, between
the first and second 24h collection.
Reliable hydroxyproline studies can there-
fore beperformed on oneproperly collected
24h urine specimen, and this should ease
the performance of the test.
The incidence of an elevated OHP in
breast-cancer patients with negative X-
rays was 11/44 (25%), 5/34 (15%), 8/34
(19%) for the Ellis/Goldberg, Hypronos-
ticon and Grant methods respectively.
Previous reports (Guzzo et al., 1969;
Cuschieri and Felgate, 1972; Cuschieri,
1973; Roberts et al., 1975; Powles et al.,
1975) have shown that the majority of
patients with negative X-rays but with a
persistent elevation of OHP subsequently
develop radiologically demonstrable
metastases. In the present study, the
follow-up period has been too short to
permit confirmation ofthe predictive value
of elevated OHP in cases of breast cancer
with negative X-rays.
In the X-ray+ breast cancer group,
5/17 patients had normal OHP when
measured by Hypronosticon method
(29.4% false negatives) as opposed to
1/20 (5%) and 1/21 (4*8%) for the Ellis/
GoldbergandGrantmethodsofestimation.
Finally, the results of the present study
have confirmed the usefulness of the
estimationofurinaryhydroxyproline inthe
detection of osseous spread from primary
breast cancer. It is, therefore, a valuable
test in staging the extent ofthe disease.
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